Compare · PYPD vs RMD
PYPD vs RMD
Side-by-side comparison of PolyPid Ltd. (PYPD) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PYPD and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $32.93B, about 256.9x PYPD ($128.2M).
- Over the past year, PYPD is up 74.6% and RMD is down 6.9% - PYPD leads by 81.5 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- RMD has more recent analyst coverage (25 ratings vs 7 for PYPD).
- Company
- PolyPid Ltd.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $128.2M
- $32.93B
- 1M return
- +33.30%
- +0.02%
- 1Y return
- +74.60%
- -6.88%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 6
- Recent ratings
- 7
- 25
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest PYPD
- PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
- Oppenheimer initiated coverage on PolyPid Ltd. with a new price target
- PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
- PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
- SEC Form 6-K filed by PolyPid Ltd.
- European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
- SEC Form 6-K filed by PolyPid Ltd.
Latest RMD
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.
- Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
- Global General Counsel Rider Michael J sold $102,000 worth of ResMed Common Stock (400 units at $255.00) as part of a pre-agreed trading plan (SEC Form 4)
- Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
- Chairman and CEO Farrell Michael J. sold $1,129,637 worth of ResMed Common Stock (4,991 units at $226.33) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.